Moderna shares are trading higher after the EMA Committee for Medicinal Products for Human Use adopted an opinion recommending authorization of the company's updated COVID-19 vaccine in the EU.
Portfolio Pulse from Benzinga Newsdesk
Moderna's shares are trading higher following the recommendation by the EMA Committee for Medicinal Products for Human Use for the authorization of the company's updated COVID-19 vaccine in the EU.
September 14, 2023 | 3:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's stock is trading higher due to the EMA Committee's recommendation for the authorization of its updated COVID-19 vaccine in the EU.
The EMA Committee's recommendation for the authorization of Moderna's updated COVID-19 vaccine in the EU is a positive development for the company. This could potentially increase the company's vaccine sales in the EU, thereby boosting its revenues and positively impacting its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100